Title : Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.

Pub. Date : 2015

PMID : 25999728






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. Metformin dipeptidyl peptidase 4 Homo sapiens
2 Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. Metformin dipeptidyl peptidase 4 Homo sapiens
3 Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. Metformin dipeptidyl peptidase 4 Homo sapiens
4 Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. Metformin dipeptidyl peptidase 4 Homo sapiens